- World rank, all time
- #31,992 of 34,923
- Rank in United States
- #6,738 of 7,310
- Research works
- 185 ▲ 74% vs 2018-21
- Citations
- 3.7k 20.2 per fractional work
- Top-10% rate
- 13.9% all institutions 10.0%
- vs its own fields
- 0.93× 1.00× is exactly expected
- Open access
- 45% world 40%
- International
- 39% world 18%
Which fields of science does Vifor Pharma (United States) work in?
In 2022-now, 52% of research at Vifor Pharma (United States) is in Health Sciences, 25% in Life Sciences. Its largest fields are Medicine (49%), Biochemistry, Genetics and Molecular Biology (16%), Economics, Econometrics and Finance (5%). It does 2.1× the world's share of Health Sciences.
Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.
Its 4 domains and 18 fields, with their numbers
- Health Sciences3552.2%
- Medicine3349.3%
- Nursing12.2%
- Health Professions00.6%
- Veterinary00.1%
- Life Sciences1725.0%
- Physical Sciences812.2%
- Chemistry34.0%
- Computer Science23.1%
- Engineering22.8%
- Materials Science11.7%
- Environmental Science00.6%
- Social Sciences710.6%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Nursing, 4.5×. Every wedge is a field page.
All 18 fields, with their numbers
- Nursing4.51×2 works
- Pharmacology, Toxicology and Pharmaceutics4.37×1 works
- Immunology and Microbiology4.36×3 works
- Biochemistry, Genetics and Molecular Biology2.93×10 works
- Medicine2.57×33 works
- Chemistry2.53×3 works
- Economics, Econometrics and Finance2.37×3 works
- Business, Management and Accounting0.97×2 works
- Neuroscience0.81×1 works
- Veterinary0.74×0 works
- Materials Science0.48×1 works
- Agricultural and Biological Sciences0.44×1 works
- Computer Science0.40×2 works
- Health Professions0.22×0 works
- Engineering0.19×2 works
- Psychology0.16×0 works
- Social Sciences0.15×1 works
- Environmental Science0.12×0 works
- Nursing 4.5×
- Pharmacology, Toxicology and Pharmaceutics 4.4×
- Immunology and Microbiology 4.4×
- Biochemistry, Genetics and Molecular Biology 2.9×
- Medicine 2.6×
- Chemistry 2.5×
- Economics, Econometrics and Finance 2.4×
- Business, Management and Accounting 1.0×
- Neuroscience 0.8×
- Veterinary 0.7×
- Materials Science 0.5×
- Agricultural and Biological Sciences 0.4×
- Computer Science 0.4×
- Health Professions 0.2×
- Engineering 0.2×
- Psychology 0.2×
- Social Sciences 0.1×
- Environmental Science 0.1×
Who are the top researchers at Vifor Pharma (United States)?
Ranked on the quality score, Alain Romero, Priyajeet S. Parekh and Susan P. Arthur lead among researchers whose main affiliation is Vifor Pharma (United States).
- 1
Alain Romero
United States · #790,912 worldwide 2k citations · 28 works
- 2
Priyajeet S. Parekh
United States · #2,326,220 worldwide 261 citations · 20 works
- 3
Susan P. Arthur
United States · #3,106,432 worldwide 887 citations · 27 works
- 4
Christopher G. Rowan
United States · #3,130,153 worldwide 936 citations · 52 works
- 5
Jennifer A. Kammerer
United States · #3,296,956 worldwide 99 citations · 22 works
- 6
Peter Geisser
United States · #3,498,926 worldwide 1.1k citations · 38 works
- 7
Jeanene Fogli
United States · #3,516,940 worldwide 526 citations · 20 works
- 8
Paula J. Alvarez
United States · #3,956,384 worldwide 382 citations · 31 works
- 9
Steven D. Woods
United States · #5,094,724 worldwide 361 citations · 27 works
Which keywords describe research at Vifor Pharma (United States)?
By fractional works in 2022-now, weighted toward what it does more of than the world: Inflammation, Cancer Therapy, Chronic Kidney Disease, Heart Failure, Oxidative Stress, Immunotherapy, Cardiovascular Disease and Anemia.
- Skin Microbiome
- Filaggrin
- Health Utility Measures
- Drug Development Costs
- Tumor Regression
- Iron Regulation
- Economic Evaluation
- Transcriptional Regulation
- Cancer Treatment
- Tumor Targeting
- Cell Death
- Immune Response
- Renin-Angiotensin-Aldosterone System Inhibitors
- Neuroprotection
- Clinical Trials
- Anemia
- Immunotherapy
- Heart Failure
- Cancer Therapy
- Epidemiology
- Inflammation
- Oxidative Stress
- Chronic Kidney Disease
- Cardiovascular Disease
- Quality of Life
- Iron Deficiency
- Hyperkalemia
- Prognostic Factors
- Drug Delivery
- Neurological Disorders
- Rituximab
- Nutrition
- Lymphoma
- Cancer Immunotherapy
- Hepcidin
- Neurodegeneration
- Cost-effectiveness Analysis
- Generic Drugs
- Immune Dysregulation
- Mutation
Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Inflammation5▲ 3.5×20 topics
- Epidemiology4▲ 1.52×22 topics
- Oxidative Stress4▲ 3.4×13 topics
- Cancer Therapy3▲ 8.7×14 topics
- Chronic Kidney Disease3▲ 20×5 topics
- Heart Failure3▲ 11×4 topics
- Cardiovascular Disease3▲ 3.9×10 topics
- Immunotherapy3▲ 5.7×10 topics
- Quality of Life2▲ 2.3×6 topics
- Anemia2▲ 33×2 topics
- Iron Deficiency2▲ 61×2 topics
- Clinical Trials2▲ 4.4×8 topics
- Hyperkalemia2▲ 176×1 topic
- Neuroprotection2▲ 7.6×3 topics
- Prognostic Factors2▲ 6.1×7 topics
- Renin-Angiotensin-Aldosterone System Inhibitors2▲ 176×1 topic
- Drug Delivery2▲ 4.6×4 topics
- Immune Response2▲ 4.4×8 topics
- Neurological Disorders2▲ 4.5×5 topics
- Cell Death2▲ 9.8×5 topics
- Rituximab2▲ 16×3 topics
- Tumor Targeting2▲ 13×3 topics
- Nutrition2▲ 5.2×5 topics
- Cancer Treatment1▲ 8.9×5 topics
- Lymphoma1▲ 13×2 topics
- Transcriptional Regulation1▲ 12×5 topics
- Cancer Immunotherapy1▲ 12×3 topics
- Economic Evaluation1▲ 16×2 topics
- Hepcidin1▲ 51×1 topic
- Iron Regulation1▲ 51×1 topic
- Neurodegeneration1▲ 6.6×5 topics
- Tumor Regression1▲ 18×2 topics
- Cost-effectiveness Analysis1▲ 24×1 topic
- Drug Development Costs1▲ 71×1 topic
- Generic Drugs1▲ 71×1 topic
- Health Utility Measures1▲ 24×1 topic
- Immune Dysregulation1▲ 23×2 topics
- Filaggrin1▲ 34×1 topic
- Mutation1▲ 9.2×3 topics
- Skin Microbiome1▲ 34×1 topic
Which research topics does Vifor Pharma (United States) publish most on?
By volume in 2022-now: Potassium and Related Disorders, Iron Metabolism and Disorders, Health Systems, Economic Evaluations, Quality of Life and Pharmaceutical Economics and Policy.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Potassium and Related Disorders Pulmonary and Respiratory Medicine 2 works
- 2 Iron Metabolism and Disorders Hematology 1 works
- 3 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 1 works
- 4 Pharmaceutical Economics and Policy Economics and Econometrics 1 works
- 5 Dermatology and Skin Diseases Dermatology 1 works
- 6 Amyotrophic Lateral Sclerosis Research Neurology 1 works
- 7 Protein Degradation and Inhibitors Molecular Biology 1 works
- 8 CAR-T cell therapy research Oncology 1 works
- 9 COVID-19 diagnosis using AI Radiology, Nuclear Medicine and Imaging 1 works
- 10 Innovation and Socioeconomic Development Business and International Management 1 works
How open and international is its research?
Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 40% of research is openly available.
World: 18% is written across borders.
How has Vifor Pharma (United States)'s research output changed?
Output in 2022-2025 was 74% higher than in 2018-2021.
The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.
Its share of all research
Growing output can still be a shrinking share: all of science grows. This is Vifor Pharma (United States) as a percentage of every work published that year, 0.00029% in 2024.
Fractional works of Vifor Pharma (United States) over all fractional works that year. How the balance of science has shifted.
Other research institutions in Somerset
- ProCure (United States)
- Montgomery High School
- University Orthopaedic Associates
- Catalent (United States)
- Terumo (United States)
- Orthopaedic Center of New Jersey
- NEI Corporation (United States)
- Light Age (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.
Discussion
Ask a question or share a note about Vifor Pharma (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.
